Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

NCI study: Interferon may reduce severity of COVID-19 in people with genetic factors

July 15, 2022
Vol.48 No.28
Clinical Roundup

NCI study: COVID-19 was third leading cause of death in the U.S. in 2020 and 2021

July 08, 2022
Vol.48 No.27
NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

June 24, 2022
Vol.48 No.25
By Paul Goldberg and Alice Tracey
NCI BSA approves eight new, nine reissued concepts

NCI BSA approves eight new, nine reissued concepts

June 24, 2022
Vol.48 No.25
By Alice Tracey
Julie Bauman: Washington, DC, needs one more NCI-designated cancer center­—and it matters that a woman runs it
Conversation with The Cancer Letter

Julie Bauman: Washington, DC, needs one more NCI-designated cancer center­—and it matters that a woman runs it

June 17, 2022
Vol.48 No.24
By Paul Goldberg
NCI, CRUK award $100M in Cancer Grand Challenge grants

NCI, CRUK award $100M in Cancer Grand Challenge grants

June 17, 2022
Vol.48 No.24
By Alice Tracey
Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0
NCI

Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0

June 17, 2022
Vol.48 No.24
By Alice Tracey
ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV
Trials & Tribulations

ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV

June 17, 2022
Vol.48 No.24
By Joel M. Palefsky and Robert Yarchoan
Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

June 10, 2022
Vol.48 No.23
By Alice Tracey
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure

Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure

May 27, 2022
Vol.48 No.21
By Paul Goldberg

Posts navigation

Previous1…313233…38Next

Trending Stories

  • FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
    “Patients are owed another review.”
  • Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
  • By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
    Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”
  • ASCO & The Conquer Cancer Foundation announce merit awards
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Benjamin Ebert, Amy Gladfelter, Stephen Liberles, and Pardis Sabeti are among new members of the National Academy of Sciences

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account